Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB


News SummaryMost relevantAll newsSector news 

Biogen Idec Inc. : Biogen Sees Positive Results From First Year of MS Treatment Study

share with twitter share with LinkedIn share with facebook
share via e-mail
03/20/2013 | 01:06pm CET
   By Saabira Chaudhuri 

Biogen Idec Inc. (BIIB) said it has seen positive results from the first year of a two-year late-stage study of its investigational candidate for a type of multiple sclerosis.

Biogen said results from its two-year pivotal Phase 3 "Advance" study of Plegridy, its investigational candidate for relapsing-remitting multiple sclerosis dosed once every two weeks or every four weeks, indicate that Plegridy significantly reduced multiple sclerosis disease activity, including relapses, disability progression and brain lesions, compared with placebo at one year.

"These full first-year results provide a more complete picture of Plegridy and its positive effects on the reduction of relapse, disability progression and lesion development," said Peter Calabresi, director at the Johns Hopkins Multiple Sclerosis Center. "These data suggest that, if approved, Plegridy may offer the benefit of a less frequent dosing schedule, which would be a meaningful advance for people living with multiple sclerosis."

Plegridy--also called peginterferon beta-1a--met the primary endpoint of reducing annualized relapse rate at one year by 36% compared with placebo. It also met its secondary endpoint, reducing the proportion of patients who relapsed by 39% compared with placebo. Additionally, it significantly reduced the number of gadolinium-enhancing lesions by 86% compared with placebo.

Biogen described Plegridy as a new molecular entity in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body, enabling study of a less-frequent dosing schedule. The investigational drug candidate is a member of the interferon class of treatments and, if approved, would be a new addition to this class, which often is used as a first-line treatment for multiple sclerosis.

The latest announcement comes after, in January, Biogen said data from a late-stage trial of Plegridy were positive. At the time, Biogen said the study's primary endpoint was met for both the two-week and four-week dose regimens. Results showed that Plegridy also met the secondary endpoints. It noted that with both dose regimens studied the risk-benefit profile of Plegridy appears to be favorable.

Also in January, Biogen reported its fourth-quarter earnings fell 2.7% as the biotechnology company's preparations to launch a new drug for multiple sclerosis increased expenses and masked revenue growth from its existing multiple sclerosis treatment.

Shares closed Tuesday at $175.61 and were inactive in recent premarket trading. The stock has risen 47% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOGEN INC
12:17a BIOGEN : Presents Data from Phase 1b Study of Investigational Alzheimer’s ..
12/08 BIOGEN INC : Lundin Law PC Announces Securities Class Action Lawsuit against Bio..
12/08 BIOGEN INC : Investor Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Shareho..
12/07 BIOGEN INC : Khang & Khang LLP Announces Securities Class Action Lawsuit against..
12/05 BIOGEN INC : Lundin Law PC Announces Securities Class Action Lawsuit against Bio..
12/05 BIOGEN INC : Shareholder Alert - - Bronstein, Gewirtz & Grossman, LLC Reminds In..
12/03 BIOGEN : Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Lif..
12/01 BIOGEN INC : Khang & Khang LLP Announces Securities Class Action Lawsuit against..
12/01 BIOGEN INC : Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actio..
11/30 BIOGEN INC : Lundin Law PC Announces Securities Class Action Lawsuit against Bio..
More news
Sector news : Biopharmaceuticals
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
12/07DJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal
More sector news : Biopharmaceuticals
News from SeekingAlpha
04:24a They're Definitely High On Something
12/08 Biogen perks up on leaked trial data on Alzheimer's candidate aducanumab
12/06 Seattle's Aspirations Versus Big Pharma's Appetites
12/02 STOCK EXCHANGE : Model Picks Teach Us To Manage Risk
Financials ($)
Sales 2016 11 531 M
EBIT 2016 6 101 M
Net income 2016 4 136 M
Debt 2016 498 M
Yield 2016 -
P/E ratio 2016 15,44
P/E ratio 2017 15,04
EV / Sales 2016 5,51x
EV / Sales 2017 5,23x
Capitalization 62 997 M
More Financials
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 340 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
George A. Scangos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
Adriana Karaboutis Executive VP-Technology & Business Solutions
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC-6.87%62 997
CSL LIMITED-8.47%32 515
GRIFOLS SA-21.37%11 420
More Results